Open AccessIbrutinib Plus Rituximab Improves Survival in Younger CLL Patients
Author(s) -
Mark L. Fuerst
Publication year - 2019
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000552837.20743.04
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , rituximab , fludarabine , oncology , alemtuzumab , leukemia , immunotherapy , cyclophosphamide , immunology , chemotherapy , lymphoma , transplantation , cancer